Abstract 2216: Risk of Stent Thrombosis After Sirolimus versus Paclitaxel-Eluting Stents. A Meta-Analysis from Nine Randomized Trials
Due to their different mechanisms of action (sirolimus is cytostatic, and paclitaxel is cytotoxic), the risk of stent thrombosis after sirolimus (SES) and paclitaxel (PES) eluting stents could be different.
Methods: We performed a meta-analysis from 9 randomized trials that compared SES and PES: TAXI (n = 202), REALITY (1,353), SIRTAX (n = 1,012), ISAR-DIABETES (n = 250), ISAR-DESIRE (n = 200), CORPAL (n = 652), ISAR-SMART-3 (n = 360), BASKET (n = 545), and ISAR-TEST (n = 450). The number of patients included in the 9 trials was 5,024 (2,514 SES, and 2,510 PES). The usual meta-analytic techniques were used (random effect or fixed effect model accordingly to the Q-test for heterogeneity).
Results: There was no heterogeneity among the trials (Q test for heterogeneity: Chi2: 5.41; DF = 6 (p = 0.49); I2: 0%). Out of the 5,024 patients, 46 suffered stent thrombosis (0.92%). This incidence was not significantly different between SES and PES: 0.83% (21/2,514) vs. 0.99% (25/2510), respectively (RR:1.2;IC 95%:0.7, 2.4;p = 0.57) (see figure⇓).
Conclusion: the risk of stent thrombosis does not significantly differ between SES and PES.